{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T16:15:23Z","timestamp":1788970523766,"version":"build-2803163510"},"reference-count":23,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2006,6]]},"DOI":"10.1016\/j.clon.2005.12.008","type":"journal-article","created":{"date-parts":[[2006,1,20]],"date-time":"2006-01-20T08:13:12Z","timestamp":1137744792000},"page":"410-418","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["An Electrodiagnostic Evaluation of the Effect of Pre-existing Peripheral Nervous System Disorders in Patients Treated with the Novel Proteasome Inhibitor Bortezomib"],"prefix":"10.1016","volume":"18","author":[{"given":"M.D.","family":"Stubblefield","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Slovin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"MacGregor-Cortelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Muzzy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Scher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Esseltine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Schenkein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.A.","family":"O'Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clon.2005.12.008_bib1","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1081\/CNV-120018236","article-title":"Chemotherapy-induced peripheral neuropathy","volume":"21","author":"Visovsky","year":"2003","journal-title":"Cancer Invest"},{"key":"10.1016\/j.clon.2005.12.008_bib2","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1016\/S0959-8049(02)00229-0","article-title":"Current status and future prospects for the treatment of chemotherapy-induced peripheral neurotoxicity","volume":"38","author":"Cavaletti","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clon.2005.12.008_bib3","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1212\/01.WNL.0000043691.53710.53","article-title":"Toxic neuropathy in patients with pre-existing neuropathy","volume":"60","author":"Chaudhry","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.clon.2005.12.008_bib4","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/1097-0142(19950301)75:5<1141::AID-CNCR2820750514>3.0.CO;2-U","article-title":"Peripheral neurotoxicity of taxol in patients previously treated with cisplatin","volume":"75","author":"Cavaletti","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.clon.2005.12.008_bib5","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/00043426-200304000-00010","article-title":"Vincristine-induced neuropathy as the initial presentation of Charcot\u2013Marie\u2013Tooth disease in acute lymphoblastic leukemia: a pediatric oncology group study","volume":"25","author":"Chauvenet","year":"2003","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.clon.2005.12.008_bib6","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/00019052-199910000-00010","article-title":"Chemotherapeutic neuropathy","volume":"12","author":"Windebank","year":"1999","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.clon.2005.12.008_bib7","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0733-8619(02)00034-8","article-title":"Neurologic complications of cancer therapy","volume":"21","author":"Plotkin","year":"2003","journal-title":"Neurol Clin"},{"key":"10.1016\/j.clon.2005.12.008_bib8","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","article-title":"Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma","volume":"23","author":"O'Connor","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clon.2005.12.008_bib9","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3816\/CLM.2004.n.003","article-title":"Update on the proteasome inhibitor bortezomib in hematologic malignancies","volume":"4","author":"Goy","year":"2004","journal-title":"Clin Lymphoma"},{"key":"10.1016\/j.clon.2005.12.008_bib10","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1001\/archneur.1994.00540190110024","article-title":"Taxol neuropathy: electrodiagnostic and sural nerve biopsy findings","volume":"51","author":"Sahenk","year":"1994","journal-title":"Arch Neurol"},{"key":"10.1016\/j.clon.2005.12.008_bib11","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1097\/00019052-200210000-00015","article-title":"Recent advances in drug-induced neuropathies","volume":"15","author":"Peltier","year":"2002","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.clon.2005.12.008_bib12","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0733-8619(18)31006-5","article-title":"Neurologic complications of systemic cancer","author":"Patchell","year":"1985","journal-title":"Neurol Clin"},{"key":"10.1016\/j.clon.2005.12.008_bib13","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0924-980X(97)00037-4","article-title":"The influence of active electrode placement on CMAP amplitude","volume":"105","author":"Bromberg","year":"1997","journal-title":"Electroencephalogr Clin Neurophysiol"},{"key":"10.1016\/j.clon.2005.12.008_bib14","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/mus.880171107","article-title":"Influence of recording site on CMAP amplitude on its variation over a length of nerve","volume":"17","author":"Van Dijik","year":"1994","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.clon.2005.12.008_bib15","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/01.PHM.0000057222.01180.62","article-title":"Reference values for peroneal nerve motor conduction to the tibialis anterior and for peroneal vs. tibial latencies","volume":"82","author":"Buschbacher","year":"2003","journal-title":"Am J Phys Med Rehabil"},{"key":"10.1016\/j.clon.2005.12.008_bib16","series-title":"Manual of nerve conduction studies","author":"Buschbacher","year":"2000"},{"key":"10.1016\/j.clon.2005.12.008_bib17","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clon.2005.12.008_bib18","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1093\/brain\/111.3.541","article-title":"Cryoglobulinaemic neuropathy. A clinical, morphological and immunocytochemical study of 8 cases","volume":"111","author":"Nemni","year":"1998","journal-title":"Brain"},{"key":"10.1016\/j.clon.2005.12.008_bib19","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1093\/brain\/118.5.1233","article-title":"Non-Hodgkin's malignant lymphomas and peripheral neuropathies \u2014 13 cases","volume":"118","author":"Vallat","year":"1995","journal-title":"Brain"},{"key":"10.1016\/j.clon.2005.12.008_bib20","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1007\/s004150050259","article-title":"Neurological manifestation of malignant and non-malignant dysglobulinaemias","volume":"24","author":"Steck","year":"1998","journal-title":"J Neurol"},{"key":"10.1016\/j.clon.2005.12.008_bib21","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(73)93196-6","article-title":"The double crush in nerve entrapment syndromes","volume":"18","author":"Upton","year":"1973","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.clon.2005.12.008_bib22","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/(SICI)1097-4598(199901)22:1<71::AID-MUS11>3.0.CO;2-S","article-title":"An electrophysiological exploration of the double crush hypothesis","volume":"22","author":"Richardson","year":"1999","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.clon.2005.12.008_bib23","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1212\/WNL.49.1.21","article-title":"Double crush syndrome: a critical analysis","volume":"49","author":"Wilbourn","year":"1997","journal-title":"Neurology"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655505005200?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655505005200?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:30:24Z","timestamp":1760542224000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655505005200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["S0936655505005200"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2005.12.008","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2006,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An Electrodiagnostic Evaluation of the Effect of Pre-existing Peripheral Nervous System Disorders in Patients Treated with the Novel Proteasome Inhibitor Bortezomib","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2005.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}